Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

Matthew Smith; Karim Fizazi; Teuvo Tammela; Cruz Felipe Melo; Luke T. Nordquist; Diana Sofia Aleman Polanco; Urban Emmenegger; Glauco Costa Silveira; Raoul S. Concepcion; Adriano Paula; Carlos Augusto de Mendonça Beato; Neil E. Fleshner; Martin Eduardo Richardet; Iris Kuss; Marie-Aude Le Berre; Gustavo Borghesi; Toni Sarapohja; Neal Shore

doi:10.1200/JCO.2021.39.6_suppl.239

Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

Matthew Smith, Karim Fizazi, Teuvo Tammela, Cruz Felipe Melo, Luke T. Nordquist, Diana Sofia Aleman Polanco, Urban Emmenegger, Glauco Costa Silveira, Raoul S. Concepcion, Adriano Paula, Carlos Augusto de Mendonça Beato, Neil E. Fleshner, Martin Eduardo Richardet, Iris Kuss, Marie-Aude Le Berre, Gustavo Borghesi, Toni Sarapohja, Neal Shore

Research output: Other conference contribution › Abstract › Scientific

Original language	English
DOIs	https://doi.org/10.1200/JCO.2021.39.6_suppl.239
Publication status	Published - 2021
Publication type	Not Eligible

Access to Document

10.1200/JCO.2021.39.6_suppl.239

Cite this

Smith, M., Fizazi, K., Tammela, T., Felipe Melo, C., Nordquist, L. T., Aleman Polanco, D. S., Emmenegger, U., Costa Silveira, G., Concepcion, R. S., Paula, A., de Mendonça Beato, C. A., Fleshner, N. E., Richardet, M. E., Kuss, I., Le Berre, M-A., Borghesi, G., Sarapohja, T., & Shore, N. (2021). Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial. https://doi.org/10.1200/JCO.2021.39.6_suppl.239

Smith, Matthew ; Fizazi, Karim ; Tammela, Teuvo ; Felipe Melo, Cruz ; Nordquist, Luke T. ; Aleman Polanco, Diana Sofia ; Emmenegger, Urban ; Costa Silveira, Glauco ; Concepcion, Raoul S. ; Paula, Adriano ; de Mendonça Beato, Carlos Augusto ; Fleshner, Neil E. ; Richardet, Martin Eduardo ; Kuss, Iris ; Le Berre, Marie-Aude ; Borghesi, Gustavo ; Sarapohja, Toni ; Shore, Neal. / Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.

@conference{12552727c20c48f697bdbf7c2db840f5,

title = "Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial",

author = "Matthew Smith and Karim Fizazi and Teuvo Tammela and {Felipe Melo}, Cruz and Nordquist, {Luke T.} and {Aleman Polanco}, {Diana Sofia} and Urban Emmenegger and {Costa Silveira}, Glauco and Concepcion, {Raoul S.} and Adriano Paula and {de Mendon{\c c}a Beato}, {Carlos Augusto} and Fleshner, {Neil E.} and Richardet, {Martin Eduardo} and Iris Kuss and {Le Berre}, Marie-Aude and Gustavo Borghesi and Toni Sarapohja and Neal Shore",

year = "2021",

doi = "10.1200/JCO.2021.39.6_suppl.239",

language = "English",

}

Smith, M, Fizazi, K, Tammela, T, Felipe Melo, C, Nordquist, LT, Aleman Polanco, DS, Emmenegger, U, Costa Silveira, G, Concepcion, RS, Paula, A, de Mendonça Beato, CA, Fleshner, NE, Richardet, ME, Kuss, I, Le Berre, M-A, Borghesi, G, Sarapohja, T & Shore, N 2021, 'Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial'. https://doi.org/10.1200/JCO.2021.39.6_suppl.239

Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial. / Smith, Matthew; Fizazi, Karim; Tammela, Teuvo; Felipe Melo, Cruz; Nordquist, Luke T.; Aleman Polanco, Diana Sofia; Emmenegger, Urban; Costa Silveira, Glauco; Concepcion, Raoul S.; Paula, Adriano; de Mendonça Beato, Carlos Augusto; Fleshner, Neil E.; Richardet, Martin Eduardo; Kuss, Iris; Le Berre, Marie-Aude; Borghesi, Gustavo; Sarapohja, Toni; Shore, Neal.

2021.

Research output: Other conference contribution › Abstract › Scientific

TY - CONF

T1 - Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

AU - Smith, Matthew

AU - Fizazi, Karim

AU - Tammela, Teuvo

AU - Felipe Melo, Cruz

AU - Nordquist, Luke T.

AU - Aleman Polanco, Diana Sofia

AU - Emmenegger, Urban

AU - Costa Silveira, Glauco

AU - Concepcion, Raoul S.

AU - Paula, Adriano

AU - de Mendonça Beato, Carlos Augusto

AU - Fleshner, Neil E.

AU - Richardet, Martin Eduardo

AU - Kuss, Iris

AU - Le Berre, Marie-Aude

AU - Borghesi, Gustavo

AU - Sarapohja, Toni

AU - Shore, Neal

PY - 2021

Y1 - 2021

UR - https://meetings.asco.org/gu/attend

U2 - 10.1200/JCO.2021.39.6_suppl.239

DO - 10.1200/JCO.2021.39.6_suppl.239

M3 - Abstract

ER -

Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

Access to Document

Other files and links

Cite this